Recognition of the multiple symptoms associated with alcohol misuse Appreciation of the importance of a comprehensive drug and alcohol history in all patients with gastroenterological and hepatic symptoms ID: 933442
Download Presentation The PPT/PDF document "Autumn 2017 GASTROENTEROLOGY" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Autumn 2017
GASTROENTEROLOGY
Slide2Recognition of the multiple symptoms associated with alcohol misuseAppreciation of the importance of a comprehensive drug and alcohol history in all patients with gastroenterological and hepatic symptoms
Explanation of the association between illicit drug use and viral hepatitisLEARNING OUTCOMES
Slide3Substances cause a range of physical problems eg vascular and carcinomatous complications of the stomach
Injecting drug users are at high risk of hepatitis B due to sharing injecting equipment and sexual contactViral hepatitis (especially hepatitis C) is common in injecting drug users and in people who snort cocaineSynthetic drugs e.g. ecstasy lead to digestive and hepatic damage, vascular complications of the stomachCONTEXT
Slide4Alcohol causes hepatitis, fibrosis and cirrhosis of the liver; colon and rectal cancerNutritional deficiencies eg vitamin B, vitamin C and iron can lead to stomatitis and glossitis
Cocaine leads to gastric ulcerations, retroperitoneal fibrosis, visceral infarction, intestinal ischemia, gastrointestinal tract perforationCONTEXT (contd)
Slide5StomatitisGlossitisReduced saliva productionEnlarged
adipose glandsLeukoplakia, erythroplakia, submucous fibrosis of oropharyngeal mucosaOral lichen planus
COMMON PRESENTATIONS
Slide6Disrupted oesophageal functionOesophagitis , gastritis, doudenitis
Oesophageal and gastric varicesMalnutrition due to altered small bowel functionAcute and chronic pancreatitisCOMMEN PRESENTATIONS (contd)
Slide7Poor diet and nutrition Poor immunity Damage to the digestive system as a result of packages of drugs being hidden in orifices
e.g. rectum, vagina or ingested Self medication in order to treat heartburn and acid indigestionGastro intestinal bleeding including Mallory-Weiss tearSPECIAL FEATURES
Slide8Patients may not consider the effect that their substance use has on their systemFear of symptoms which may be life threateningLack of detection of recognition by doctors in screening for substance use in patients presenting with gastro intestinal disorders
BARRIERS TO DETECTION
Slide9A careful history with details of current and past substance misuse is essentialDetails of alcohol use are mandatoryNausea and vomiting is caused by disorders of digestive tract and the brain
Alcohol use causes pain, nausea, vomiting and hematemesis from Mallory-Weiss tears ASSESSMENT
Slide10Opioid analgesics can cause nausea and vomiting Abdominal pain, diarrhoea and constipation are common with licit and illicit drugsAcute liver failure presents with deepening jaundice, confusion, coma and death is caused by many drugs particularly ecstasy
Cocaine can present with ischemic colitis from intestinal thrombosisASSESSMENT (contd)
Slide11Since 1988 injecting drug users have been targeted for vaccinationAvailability of vaccination and uptake remains poor so needs to be proactive A harm reduction approach is the focus of management
Diagnosis includes endoscopy, histopathological testing, x-rays, scans, routine blood testsAlcohol detoxification should be consideredTREATMENT
Slide12Reduction of harmful drugs and substitute medication eg methadone should be prescribedIf reduction is declines, reduction of harmful practices should be encouraged
Safe injecting practices, vaccination for BBV, and provision of clean injecting equipmentAll patients must be tested for hepatitis and appropriate therapy offeredTREATMENT(contd)
Slide13Vaccinate all drug users against Hepatitis A as they at risk due to poor living conditions and fecal contamination of drugs and injecting equipment
Hepatitis A is available as a single component vaccine and combined with hepatitis B Single component hepatitis A vaccine is preferable to combined hepatitis A and B vaccineFor single vaccine give 2 doses and second dose after 6-12 monthsThe second dose may be delayed for up to 3 yearsWhen deciding on the optimal regime consider if the patient will return for subsequent doses
HEPATITIS A
Slide14About 21% of injecting drug users have past or current hepatitis infectionVaccinate all drug users against hepatitis BUse accelerated 0, 7and 21 days schedule to complete the course as quickly as possible
Partners and children should be offered vaccination HEPATITIS B
Slide15Screening and diagnosis of infection enables patients to understand how they can implement life changes to slow the rate of progressionThere is no vaccine available
Consider anti viral treatment in chronic hepatitis CHEPATITIS C
Slide16Referral to specialist addiction services for further assessment, advice and treatmentThis may include motivational interviewing, group, individual or family behavioural treatments to reduce substance use
Primary care teams can advise and monitor gastrointestinal symptoms and may have the skills to manage substance problemsREFERRAL, NETWORKS AND SERVICES
Slide17Substances and associated conditions
Slide18Appleby, VJ;
Darnbrough,E;
Forrester,K; Simpson,R;
Clarke,C; Moreea
S. (2015) PTU-118 An audit of the prevalence of chronic hepatitis c and treatment outcomes in drug users attending substance misuse centres in Bradford – planning for future service provision Gut ;64:A114 doi:10.1136/gutjnl-2015-309861.233
http://
gut.bmj.com/content/64/Suppl_1/A114.1.abstract?eaf
Badrakalimuthu
, V.R,
Rumball
, D & Chawla, A (2011)
Hepatitis
C: a patient’s journey from a psychiatrists’ perspective. Advances in psychiatric treatment.
Barclay, G.A, Stewart, J.B, Day, C.P and Gilvarry, E (2008) Adverse physical effects of alcohol misuse. Advances in psychiatric treatment. Vol.14,
139-151
EASL Hepatitis C Guidelines
2016
:
http
://
www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2016
Kumar P and Clark M (2009) Clinical Medicine. 7th
edn
. London: Elsevier
NICE (2004) Hepatitis C - pegylated interferons, ribavirin and alfa interferon (NICE technology appraisal,TA75) http://guidance.nice.org.uk/TA75
This
guidance replaces Hepatitis C - alpha interferon and ribavirin (TA14).
This
guidance is extended by Hepatitis C -
peginterferon
alfa and ribavirin
(
TA106).
http://
guidance.nice.org.uk/TA75
NICE (2006) Hepatitis B (chronic)
-
adefovir
dipivoxil
and pegylated interferon alpha-2a (NICE technology appraisal,TA96)
http://
guidance.nice.org.uk/TA96
This
guidance has been partially updated by CG165 Hepatitis B (chronic
)
NICE (2013) Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people and adults
http://
www.nice.org.uk/guidance/cg165
NICE (2010) Hepatitis C - peginterferon alfa and ribavirin (NICE technology appraisal,TA200) http://guidance.nice.org.uk/TA200Public Health England. Health Protection Report II (26) July 28 2017. Hepatitis C in the UK Annuals Report https://www.gov.uk/government/publications/health-protection-report-volume-11-2017/hpr-volume-11-issue-26-news-28-july
REFERENCES